2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Rick A. NishimuraProfessor of Cardiovascular Diseases, Mayo Clinic

“There is a knowledge explosion in medicine today, which can overwhelm the clinician. This is particularly true in the area of valvular heart disease, in which multiple investigational trials are being rapidly performed and released, so that it becomes extremely difficult for an individual clinician to keep up with optimal treatments for each specific patient. The Valvular Heart Disease Guideline brings together experts in the field who review all the data and arrive at a consensus opinion for best treatment, outlined in the class recommendations.”

Catherine OttoProfessor of Medicine, University of Washington

“Current research and new technology continue to transform the treatment of heart valve disease, as updated lifestyle and medication guidance evolve and less invasive procedures have replaced traditional surgery for many patients.”

“Specifically, there's increasing expectation on the part of our patients and the public at large that TAVI should be available to all patients. I think that's a very important distinction to make when counseling younger patients with respect to what is available with regard to the [literature].”